Cure8 news brief
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis — potentially offering an oral option that concentrates in the intestine.
Patients with Crohn's disease or ulcerative colitis (including those on biologics), clinicians treating IBD, and researchers interested in intestine-targeted small-molecule therapies and biomarker development.
The findings come from very small, open-label Phase 1b cohorts (five Crohn's patients and five UC patients) without placebo controls. In the Crohn's cohort, mean endoscopic disease activity declined and fecal calprotectin fell; tissue analyses showed increased ileal cAMP consistent with PDE4 engagement and reductions in inflammatory-cell populations.
One patient had an initially non-traversable stricture become traversable after 14 days, but the company cautioned this single observation does not prove antifibrotic benefit.
Safety and next steps: Reported adverse events in the Crohn's cohort were mild with no serious adverse events; larger, controlled Phase 2 studies are underway or planned (including a Phase 2b UC trial and a Phase 2a Crohn's study) to test efficacy, safety, and durability.
Bottom line: These are encouraging early translational signals but they come from very small, short-duration, uncontrolled cohorts — confirmatory randomized trials are needed.
The reported results are from very small (n=5) open-label cohorts and short treatment periods without placebo controls; observed biomarker and endoscopic changes are preliminary. PALI-2108 is investigational and not approved. The company itself notes larger controlled studies are needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
